Summary
4.30 0.05(1.18%)07/01/2024
Macrogenics Inc (MGNX)
Macrogenics Inc (MGNX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.30 | -4.66 | -4.02 | -69.31 | -57.76 | -20.07 | -75.13 | -82.79 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.30 | |
| Open | 4.19 | |
| High | 4.48 | |
| Low | 4.19 | |
| Volume | 962,082 | |
| Change | 0.06 | |
| Change % | 1.30 | |
| Avg Volume (20 Days) | 1,132,422 | |
| Volume/Avg Volume (20 Days) Ratio | 0.85 | |
| 52 Week Range | 3.15 - 21.88 | |
| Price vs 52 Week High | -80.35% | |
| Price vs 52 Week Low | 36.51% | |
| Range | 2.63 | |
| Gap Up/Down | -0.15 | |
Fundamentals | ||
| Market Capitalization (Mln) | 266 | |
| EBIDTA | -174,494,752 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0100 | |
| WallStreet Target Price | 24.80 | |
| Book Value | 2.4590 | |
| Earnings Per Share | -0.1500 | |
| EPS Estimate Current Quarter | -0.1500 | |
| EPS Estimate Next Quarter | -0.4900 | |
| EPS Estimate Current Year | -2.4800 | |
| EPS Estimate Next Year | -1.8200 | |
| Diluted EPS (TTM) | -0.1500 | |
| Revenues | ||
| Profit Marging | -0.5360 | |
| Operating Marging (TTM) | -5.9040 | |
| Return on asset (TTM) | -0.3633 | |
| Return on equity (TTM) | -0.0615 | |
| Revenue TTM | 43,357,000 | |
| Revenue per share TTM | 0.6990 | |
| Quarterly Revenue Growth (YOY) | -0.6280 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -62,469,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.1984 | |
| Revenue Enterprise Value | 15.7839 | |
| EBITDA Enterprise Value | 447.5599 | |
| Shares | ||
| Shares Outstanding | 62,560,500 | |
| Shares Float | 52,276,807 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.20 | |
| Insider (%) | 2.61 | |
| Institutions (%) | 102.82 | |
07/01 11:45 EST - accesswire.com
Levi & Korsinsky Reminds Shareholders of an Investigation into MacroGenics, Inc. (MGNX) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
Levi & Korsinsky Reminds Shareholders of an Investigation into MacroGenics, Inc. (MGNX) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
07/01 11:20 EST - accesswire.com
MGNX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of MacroGenics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
MGNX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of MacroGenics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
07/01 11:00 EST - accesswire.com
The Schall Law Firm Embarks On A Review Of Allegations Against MacroGenics Inc And Encourages Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Embarks On A Review Of Allegations Against MacroGenics Inc And Encourages Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/30 11:57 EST - globenewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. – MGNX
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. – MGNX
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
06/30 11:15 EST - accesswire.com
MacroGenics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MGNX
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
MacroGenics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MGNX
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
06/30 11:13 EST - accesswire.com
MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
06/30 11:00 EST - accesswire.com
The Schall Law Firm Launches An Inquiry Into Charges Against MacroGenics Inc And Calls On Its Shareholders To Get In Touch
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Launches An Inquiry Into Charges Against MacroGenics Inc And Calls On Its Shareholders To Get In Touch
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/29 21:01 EST - accesswire.com
Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - MGNX
NEW YORK, NY / ACCESSWIRE / June 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - MGNX
NEW YORK, NY / ACCESSWIRE / June 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
06/29 11:00 EST - accesswire.com
The Schall Law Firm Begins A Scrutiny Into Accusations Against MacroGenics Inc And Invites Its Shareholders To Communicate
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins A Scrutiny Into Accusations Against MacroGenics Inc And Invites Its Shareholders To Communicate
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/28 11:30 EST - accesswire.com
MacroGenics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - MGNX
NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
MacroGenics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - MGNX
NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
06/28 11:00 EST - accesswire.com
The Schall Law Firm Is Initiating A Probe Into Claims Against MacroGenics Inc And Urges Its Shareholders To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Initiating A Probe Into Claims Against MacroGenics Inc And Urges Its Shareholders To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/27 14:00 EST - accesswire.com
MacroGenics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- MGNX
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
MacroGenics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- MGNX
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
06/27 13:45 EST - accesswire.com
The Schall Law Firm Initiates A Probe Into Claims Against MacroGenics Inc And Urges Its Shareholders To Connect
LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates A Probe Into Claims Against MacroGenics Inc And Urges Its Shareholders To Connect
LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/26 16:20 EST - accesswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ:MGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ:MGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
06/26 14:00 EST - accesswire.com
The Schall Law Firm Is Starting An Investigation Into Allegations Against MacroGenics Inc And Encourages Its Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Starting An Investigation Into Allegations Against MacroGenics Inc And Encourages Its Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
06/25 13:30 EST - accesswire.com
An Investigation Has Commenced on Behalf of MacroGenics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MGNX Losses.
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.
An Investigation Has Commenced on Behalf of MacroGenics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MGNX Losses.
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.